Can Verastem Recover After Failure?
This article was originally published in Scrip
You may also be interested in...
Biotech heavyweights Henri Termeer and Christoph Westphal have left struggling stem cell focused cancer company Verastem without warning in a shake-up of its board.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.